Synthetic Stock: How Ackman Doubled-Down on VRX

Some may get tired of hearing about Bill Ackman and Valeant Pharma, but I think studying this investment – its ups, downs, tricks, and traps – is a fascinating study in both the power of derivatives and that of investing bias.